KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma
KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma
About this item
Full title
Author / Creator
Cahill, Katherine N , Katz, Howard R , Cui, Jing , Lai, Juying , Kazani, Shamsah , Crosby-Thompson, Allison , Garofalo, Denise , Castro, Mario , Jarjour, Nizar , DiMango, Emily , Erzurum, Serpil , Trevor, Jennifer L , Shenoy, Kartik , Chinchilli, Vernon M , Wechsler, Michael E , Laidlaw, Tanya M , Boyce, Joshua A and Israel, Elliot
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
This proof-of-principle trial showed that imatinib treatment reduced mast-cell activation and improved airway responsiveness in patients with severe refractory asthma.
Many patients with severe asthma do not have adequate disease control despite the use of high-dose inhaled or systemic glucocorticoids.
1
Severe asthma is associated with ai...
Alternative Titles
Full title
KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5568669
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5568669
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1613125
